Activating peripheral arterial disease patients to reduce cholesterol: a randomized trial.

[1]  P. Greenland,et al.  Attitudes and behavior of peripheral arterial disease patients toward influencing their physician’s prescription of cholesterol-lowering medication , 2010, Vascular medicine.

[2]  Patrick Royston,et al.  Multiple Imputation of Missing Values: New Features for Mim , 2009 .

[3]  K. Seung,et al.  Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals , 2009, Circulation.

[4]  Luigi Ferrucci,et al.  Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. , 2009, JAMA.

[5]  E. Selvin,et al.  Contemporary risk factor control and walking dysfunction in individuals with peripheral arterial disease: NHANES 1999-2004. , 2008, Atherosclerosis.

[6]  Andreas Zeller,et al.  Patients' Self-Reported Adherence to Cardiovascular Medication Using Electronic Monitors as Comparators , 2008, Hypertension Research.

[7]  A Hofman,et al.  Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. , 2008, JAMA.

[8]  J. Price,et al.  Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. , 2006, Atherosclerosis.

[9]  Patrick Royston,et al.  Multiple Imputation of Missing Values: Update of Ice , 2005 .

[10]  J. Hibbard,et al.  Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. , 2004, Health services research.

[11]  P. Royston.  Multiple Imputation of Missing Values , 2004 .

[12]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[13]  S. Erickson,et al.  The Concordance of Self-Report With Other Measures of Medication Adherence: A Summary of the Literature , 2004, Medical care.

[14]  C. McDonald,et al.  Failure of Computerized Treatment Suggestions to Improve Health Outcomes of Outpatients with Uncomplicated Hypertension: Results of a Randomized Controlled Trial , 2004, Pharmacotherapy.

[15]  P. Greenland,et al.  Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. , 2003, Archives of internal medicine.

[16]  Tomás Pantoja,et al.  Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .

[17]  R. Kravitz,et al.  Direct observation of requests for clinical services in office practice: what do patients want and do they get it? , 2003, Archives of internal medicine.

[18]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[19]  P. Greenland,et al.  Atherosclerotic risk factor reduction in peripheral arterial disease , 2002, Journal of General Internal Medicine.

[20]  K. Tu,et al.  Can we alter physician behavior by educational methods? Lessons learned from studies of the management and follow‐up of hypertension , 2002, The Journal of continuing education in the health professions.

[21]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[22]  J. Best,et al.  Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world"--randomized controlled trial. , 2002, Journal of clinical epidemiology.

[23]  B. Svarstad,et al.  The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. , 1999, Patient education and counseling.

[24]  J. Crouse,et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. , 1999, The American journal of cardiology.

[25]  M. Hollon.  Direct-to-consumer marketing of prescription drugs: creating consumer demand. , 1999, JAMA.

[26]  J. Pincus.  Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) , 1998, The American journal of cardiology.

[27]  M. Dimatteo,et al.  Perceived Efficacy in Patient‐Physician Interactions (PEPPI): Validation of an Instrument in Older Persons , 1998, Journal of the American Geriatrics Society.

[28]  J. Kues,et al.  Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians. , 1997, Archives of family medicine.

[29]  P. Greenland,et al.  Atherosclerotic Risk Factors Are Less Intensively Treated in Patients with Peripheral Arterial Disease Than in Patients with Coronary Artery Disease , 1997, Journal of General Internal Medicine.

[30]  P. Corey,et al.  Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation. , 1979, The American journal of clinical nutrition.

[31]  G. Moneta.  Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals , 2010 .

[32]  M. Hollon.  Direct-To-Consumer Marketing of Prescription Drugs , 2004 .

[33]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[35]  M. Criqui,et al.  Peripheral arterial disease detection, awareness, and treatment in primary care. , 2001, JAMA.

[36]  P. Ryan.  Update to random allocation of treatments to blocks , 2000 .

[37]  P. Ryan.  Random allocation of treatments in blocks , 1998 .